Anti-Hypertensive Drugs - Ivory Coast

Ivory Coast

The revenue of the Anti-Hypertensive Drugs market in Ivory Coast is estimated to reach US$4.53m in 2024.
It is projected to grow at an annual growth rate (CAGR 2024-2029) of -0.45%, resulting in a market volume of US$4.43m by 2029.
When compared globally, United States is expected to generate the highest revenue in the market, amounting to US$12,290.00m in 2024.
The demand for anti-hypertensive drugs in Ivory Coast is on the rise due to the increasing prevalence of hypertension in the country.

Key regions: Japan, India, Italy, Brazil, South Korea

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Hypertensive Drugs market in Ivory Coast is experiencing a steady growth in recent years.

Customer preferences: Ivory Coast has a high prevalence of hypertension, which is a major risk factor for cardiovascular diseases. The rise in hypertension cases has led to an increase in the demand for anti-hypertensive drugs. Patients in Ivory Coast prefer affordable and effective drugs that can manage their hypertension.

Trends in the market: The Anti-Hypertensive Drugs market in Ivory Coast is dominated by imported drugs from Europe and Asia. However, there is a growing trend towards locally manufactured drugs, which are cheaper and more accessible to the local population. This trend is driven by the government's efforts to promote local pharmaceutical manufacturing and reduce the country's dependence on imported drugs.

Local special circumstances: The healthcare system in Ivory Coast is still developing, and access to healthcare services remains a challenge for many people. This has led to a high demand for over-the-counter drugs, including anti-hypertensive drugs. However, the lack of regulation and oversight of the pharmaceutical industry has led to the proliferation of counterfeit drugs, which pose a significant risk to public health.

Underlying macroeconomic factors: Ivory Coast is one of the fastest-growing economies in West Africa, with a robust pharmaceutical industry that is attracting foreign investment. The government's commitment to improving healthcare services and promoting local manufacturing is creating opportunities for local and international pharmaceutical companies to invest in the country. The rise in disposable income and the growing middle class in Ivory Coast is also driving the demand for quality healthcare services, including anti-hypertensive drugs.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.